Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Good tolerability equals good results: the patient's perspective
Autore:
Naber, D; Karow, A;
Indirizzi:
Univ Hamburg, Hosp Psychiat & Psychotherapy, D-20247 Hamburg, Germany UnivHamburg Hamburg Germany D-20247 hotherapy, D-20247 Hamburg, Germany
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
, volume: 11, anno: 2001, supplemento:, 4
pagine: 391 - 396
SICI:
0924-977X(200110)11:<391:GTEGRT>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; SCHIZOPHRENIC-PATIENTS; SUBJECTIVE EXPERIENCE; NEUROLEPTICS; SCALE; RISPERIDONE; HALOPERIDOL; CLOZAPINE; THERAPY; DRUGS;
Keywords:
antipsychotics; schizophrenia; side effects subjective effects; quality of life;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Naber, D Univ Hamburg, Hosp Psychiat & Psychotherapy, Martinistr 52, D-20247 Hamburg, Germany Univ Hamburg Martinistr 52 Hamburg Germany D-20247 burg, Germany
Citazione:
D. Naber e A. Karow, "Good tolerability equals good results: the patient's perspective", EUR NEUROPS, 11, 2001, pp. 391-396

Abstract

Although conventional antipsychotics are useful for the treatment of schizophrenia, many patients discontinue taking them within a few months. As well as the positive influence of a good doctor-patient relationship, evidencesuggests that the patient's initial subjective experience during antipsychotic therapy is a major predictor of compliance. In addition to motor symptoms, conventional antipsychotics can cause significant adverse effects on drive, emotion and cognition, which are reflected in patients complaining ofa reduced quality of life, although may not be detected by objective examination. This syndrome, which is similar to the negative symptoms of schizophrenia, is known by numerous terms including 'pharmacogenic depression' and'pharmacogenic anhedonia'. The introduction of atypical antipsychotics broadened the criteria for effective antipsychotic treatment to include the subjective assessment of improvement in patients' quality of life. The previous lack of interest in this domain may have been due to the inability to improve it with conventional agents and the misconception that schizophrenic patients were unable to subjectively evaluate their quality of life. However, numerous studies have shown that 63-95% of patients in remission are able to self-rate their affective state of well being or quality of life. Atypical antipsychotics are superior to conventional antipsychotics in improving quality of life and reducing the stigma of schizophrenia, particularly from the patient's perspective and are strong reasons for the widespread use of these drugs. (C) 2001 Elsevier Science BM All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/11/19 alle ore 03:28:40